GGrantIndex
← Leaderboards

Paul M Hassoun

Tufts Medical Center

$13,983,399
Attributed
$17,781,868
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.4M · FY200523
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$38,364,456 · 13

By mechanism

P50$23,857,429 · 3
R01$12,735,703 · 4
U01$1,098,259 · 1
R21$454,613 · 2
R03$158,112 · 1
P01$42,895 · 1

Top collaborators

Most similar at Tufts Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Molecular

Research focus

MolecularLungFunctional DisorderBlood VesselsPulmonary Arterial HypertensionHemodynamicsCessation Of LifeBaseVentricularPathway InteractionsLinkRight Ventricular FunctionResearch PersonnelGenesCardiacResponseFutureCohortConnective Tissue DiseasesProgramsRight Ventricular DysfunctionGeneticPhenotypeScleroderma

Grant awards (57)

Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH$245,853
R01 · FY2023 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH$650,223
R01 · FY2022 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH$658,783
R01 · FY2021 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH$678,878
R01 · FY2020 · HL · contact PI
Functional Impact of Col18a1/Endostatin Variants in PAH$594,522
R01 · FY2020 · HL
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH$691,560
R01 · FY2019 · HL · contact PI
Functional Impact of Col18a1/Endostatin Variants in PAH$631,666
R01 · FY2019 · HL
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$248,442
U01 · FY2019 · HL · contact PI
Prognostic Role of Plasma Xanthine Oxidoreductase in ARDS Patients$122,813
R21 · FY2019 · HL · contact PI
Functional Impact of Col18a1/Endostatin Variants in PAH$644,325
R01 · FY2018 · HL
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$330,615
U01 · FY2018 · HL · contact PI
Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension$208,987
R21 · FY2018 · AR
Prognostic Role of Plasma Xanthine Oxidoreductase in ARDS Patients$122,813
R21 · FY2018 · HL · contact PI
Functional Impact of Col18a1/Endostatin Variants in PAH$668,824
R01 · FY2017 · HL
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$157,394
U01 · FY2017 · HL · contact PI
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$83,282
U01 · FY2017 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in PAH$633,919
R01 · FY2016 · HL · contact PI
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$157,394
U01 · FY2016 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in PAH$641,968
R01 · FY2015 · HL · contact PI
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program$121,132
U01 · FY2015 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in PAH$658,659
R01 · FY2014 · HL · contact PI
Mechanisms of Right Ventricular Dysfunction in PAH$655,665
R01 · FY2013 · HL · contact PI
The Role of Xanthine Oxidoreductase in Ventilator-Associated Lung Injury$386,417
R01 · FY2013 · HL · contact PI
A Genome-wide Methylation Study of Epigenetic Contributions to PAH$77,112
R03 · FY2013 · HL
Mechanisms of Right Ventricular Dysfunction in PAH$703,702
R01 · FY2012 · HL · contact PI
The Role of Xanthine Oxidoreductase in Ventilator-Associated Lung Injury$405,900
R01 · FY2012 · HL · contact PI
Exhaled NO and Oxidative Stress in Systemic Sclerosis Pulmonary Hypertension$284,130
R01 · FY2012 · HL · contact PI
A Genome-wide Methylation Study of Epigenetic Contributions to PAH$81,000
R03 · FY2012 · HL
Molecular Determinants of Pulmonary Arterial Hypertension$4,206,260
P50 · FY2011 · HL · contact PI
SCLERODERMA-ASSOCIATED PAH$641,285
P50 · FY2011 · HL · contact PI
The Role of Xanthine Oxidoreductase in Ventilator-Associated Lung Injury$410,000
R01 · FY2011 · HL · contact PI
Administrative$116,981
P50 · FY2011 · HL · contact PI
Molecular Determinants of Pulmonary Arterial Hypertension$4,144,079
P50 · FY2010 · HL · contact PI
SCLERODERMA-ASSOCIATED PAH$582,396
P50 · FY2010 · HL · contact PI
The Role of Xanthine Oxidoreductase in Ventilator-Associated Lung Injury$410,000
R01 · FY2010 · HL · contact PI
Administrative$117,150
P50 · FY2010 · HL · contact PI
Molecular Determinants of Pulmonary Arterial Hypertension$4,098,405
P50 · FY2009 · HL · contact PI
SCLERODERMA-ASSOCIATED PAH$568,438
P50 · FY2009 · HL · contact PI
Administrative$116,039
P50 · FY2009 · HL · contact PI
Molecular Determinants of Pulmonary Arterial Hypertension$9,512
P50 · FY2009 · HL · contact PI
Molecular Determinants of Pulmonary Arterial Hypertension$4,056,519
P50 · FY2008 · HL · contact PI
SCLERODERMA-ASSOCIATED PAH$486,269
P50 · FY2008 · HL · contact PI
Administrative$113,555
P50 · FY2008 · HL · contact PI
Molecular Determinants of Pulmonary Arterial Hypertension$4,067,813
P50 · FY2007 · HL · contact PI
SCLERODERMA-ASSOCIATED PAH$414,507
P50 · FY2007 · HL · contact PI
Role of Xanthine Oxidase in Lung Injury$310,055
R01 · FY2007 · HL · contact PI
Administrative$118,221
P50 · FY2007 · HL · contact PI
Core--Tissue /biophysical$28,226
P01 · FY2007 · HL · contact PI
Role of Xanthine Oxidase in Lung Injury$319,316
R01 · FY2006 · HL · contact PI
Core--Tissue /biophysical$14,669
P01 · FY2006 · HL · contact PI
Role of Xanthine Oxidase in Lung Injury$327,000
R01 · FY2005 · HL
ECHOCARDIOGRAPHIC ASSESSMENT OF PULMONARY HYPERTENSION$17,445
M01 · FY2005 · RR
Role of Xanthine Oxidase in Lung Injury$327,000
R01 · FY2004 · HL
ROLE OF XANTHINE OXIDASE IN LUNG INJURY$146,202
R01 · FY2002 · HL
ROLE OF XANTHINE OXIDASE IN LUNG INJURY$125,561
R01 · FY2002 · HL
ROLE OF XANTHINE OXIDASE IN LUNG INJURY$266,671
R01 · FY2001 · HL
ROLE OF XANTHINE OXIDASE IN LUNG INJURY$258,904
R01 · FY2000 · HL